Canopy Growth (WEED) Aktienübersicht
Die Canopy Growth Corporation ist zusammen mit ihren Tochtergesellschaften in der Produktion, dem Vertrieb und dem Verkauf von Cannabis- und Hanfprodukten für Freizeit- und medizinische Zwecke hauptsächlich in den Vereinigten Staaten, Kanada, Deutschland und international tätig. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
WEED Community Fair Values
Create NarrativeSee what 50 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Canopy Growth Corporation Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | CA$1.29 |
| 52-Wochen-Hoch | CA$3.28 |
| 52-Wochen-Tief | CA$1.18 |
| Beta | 2.41 |
| 1 Monat Veränderung | -6.52% |
| 3 Monate Veränderung | -15.13% |
| 1 Jahr Veränderung | -11.64% |
| 3 Jahre Veränderung | -78.50% |
| 5 Jahre Veränderung | -99.47% |
| Veränderung seit IPO | -95.02% |
Aktuelle Nachrichten und Updates
Narrative-Update • Jul 02
WEED: German Medical Expansion And New Therapies Will Drive Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth, reducing the implied price target from about CA$2.33 to roughly CA$2.02 as they incorporate slightly lower projected revenue growth and a more conservative future P/E assumption. What’s in the News for Canopy Growth Canopy Growth relaunched its Tweed brand in the German medical cannabis market, introducing three MTL Cannabis strains (Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes) as part of a broader plan to expand its product portfolio in Germany through 2026.Narrative-Update • Jun 18
WEED: German Medical Relaunch Will Drive Future Upside For The Stock
Analysts have trimmed their fair value estimate for Canopy Growth to CA$2.33 from CA$2.38, citing updated assumptions around revenue growth, profit margins and the future P/E they apply to the stock. What's in the News for Canopy Growth Canopy Growth relaunched its Tweed brand in the German medical market, introducing three cannabis strains developed by its wholly owned subsidiary MTL Cannabis Corp., with plans for up to five MTL-derived strains in June 2026 and further portfolio expansion through the year.Recent updates
Narrative-Update • Jul 02
WEED: German Medical Expansion And New Therapies Will Drive Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth, reducing the implied price target from about CA$2.33 to roughly CA$2.02 as they incorporate slightly lower projected revenue growth and a more conservative future P/E assumption. What’s in the News for Canopy Growth Canopy Growth relaunched its Tweed brand in the German medical cannabis market, introducing three MTL Cannabis strains (Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes) as part of a broader plan to expand its product portfolio in Germany through 2026.Narrative-Update • Jun 18
WEED: German Medical Relaunch Will Drive Future Upside For The Stock
Analysts have trimmed their fair value estimate for Canopy Growth to CA$2.33 from CA$2.38, citing updated assumptions around revenue growth, profit margins and the future P/E they apply to the stock. What's in the News for Canopy Growth Canopy Growth relaunched its Tweed brand in the German medical market, introducing three cannabis strains developed by its wholly owned subsidiary MTL Cannabis Corp., with plans for up to five MTL-derived strains in June 2026 and further portfolio expansion through the year.
Narrative-Update • Jun 04
WEED: German Medical Relaunch And New Brand Portfolio Will Drive Upside
Analysts have adjusted their price target for Canopy Growth to CA$4.82, with updated assumptions that include a slightly higher discount rate, modestly different revenue growth expectations, a small change in projected profit margin and a revised future P/E estimate. What's in the News Relaunch of the Tweed brand in the German medical cannabis market, with three initial strains supplied by wholly owned subsidiary MTL Cannabis Corp., targeting physicians and patients familiar with the legacy brand.Narrative-Update • May 13
WEED: Expanded Product Line And Equity Raise Will Drive Future Upside
Analysts have modestly reduced their price target on Canopy Growth to CA$2.38, citing slightly higher assumed discount rates, a somewhat stronger profit margin outlook, and a lower future P/E multiple in their refreshed models. What's in the News Canopy Growth and its medical brand Spectrum Therapeutics expanded their Minor Cannabinoid softgel lineup, adding new 30 and 90 pack formats and more dosing options across the Optimized Spectrum portfolio for both daytime and nighttime use (Key Developments).Narrative-Update • Apr 26
WEED: New Brand Launch And Equity Raise Will Support Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth from CA$5.00 to CA$4.82, citing updated assumptions that include a slightly lower revenue growth outlook, a higher profit margin and a reduced future P/E multiple. What's in the News Canopy Growth launched Deelish, a new cannabis brand aimed at everyday consumers, with products positioned at everyday price points and high THC content across both flower and pre-roll formats (Key Developments).Narrative-Update • Apr 11
WEED: Everyday Brand Launch And Equity Raise Will Support Future Upside
Analysts have adjusted their CA$ price target on Canopy Growth to reflect updated views on long term revenue growth, profit margin assumptions, and a lower projected future P/E multiple. This has resulted in a slightly different outlook than before.Narrative-Update • Mar 28
WEED: Term Loan Refinancing Will Support Medical Expansion And New Formats
Analysts have reduced their Canopy Growth fair value estimate from CA$3.20 to about CA$2.38, citing updated assumptions around revenue growth, profit margins, the discount rate, and a lower expected future P/E multiple. What's in the News Canopy Growth filed a follow-on equity offering of approximately $19.27 million, covering 18,705,578 common shares priced at $1.03 each (Key Developments).Narrative-Update • Mar 13
WEED: Term Loan And Equity Raise Will Support Future Acquisitions
Analysts have trimmed their CA$ price target on Canopy Growth, citing slightly higher projected revenue growth, a lower profit margin outlook, and a higher assumed future P/E multiple. Together, these factors imply a more cautious stance on the shares.Narrative-Update • Feb 26
WEED: Term Loan And Equity Raise Will Support Future Portfolio Expansion
Analysts have adjusted their price target on Canopy Growth to CA$5.00, reflecting updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple. What's in the News Filed a follow-on equity offering of approximately $19.27 million, covering 18,705,578 common shares priced at about $1.03 per share (Key Developments).Narrative-Update • Feb 11
WEED: Term Loan Funding Will Support Expansion Of Medical And Adult-Use Portfolio
Analysts have trimmed their fair value estimate for Canopy Growth from $8.00 to $5.00, citing higher assumed revenue growth of 14.73% paired with much thinner profit margins of 4.78% and a very large 137.82x future P/E, which together point to a riskier and more expensive earnings profile. What's in the News Canopy Growth entered a term loan agreement to receive net proceeds of US$150 million from lenders led by JGB Management Inc., with the loan maturing in January 2031.Narrative-Update • Jan 27
WEED: Medical Expansion And New Product Formats Will Drive Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth from US$3.76 to about US$3.20. This reflects updated assumptions around slower revenue growth, a slightly lower future P/E, and a broadly unchanged margin and discount rate profile.Analyseartikel • Jan 11
More Unpleasant Surprises Could Be In Store For Canopy Growth Corporation's (TSE:WEED) Shares After Tumbling 28%
Canopy Growth Corporation ( TSE:WEED ) shares have had a horrible month, losing 28% after a relatively good period...Narrative-Update • Jan 11
WEED: Medical And Adult Use Product Expansion Will Drive Future Upside
Analysts have made only very small tweaks to their inputs for Canopy Growth, keeping the fair value estimate steady at $3.76 while slightly adjusting assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these changes support a largely unchanged price target outlook.Narrative-Update • Dec 23
WEED: Medical Expansion Will Drive Future Upside For Shares
Analysts have nudged their price target on Canopy Growth higher to reflect an improved fair value estimate, rising from approximately $3.30 to $3.76. This revision is supported by slightly stronger projected revenue growth, a notable uplift in expected profit margins, and a lower anticipated future price to earnings multiple.Narrative-Update • Dec 08
WEED: Medical Expansion And Share Consolidation Will Drive Future Upside
Analysts have modestly adjusted their price target on Canopy Growth, citing largely unchanged assumptions for fair value at approximately 3.30 dollars, a stable discount rate near 6.12 percent, and essentially flat outlooks for revenue growth, profit margins, and future valuation multiples. What's in the News Launched Claybourne Gassers All in One vapes featuring high potency liquid diamonds and anti clog, anti burn technology, along with new Claybourne Frosted Flyers infused pre roll variety packs in select Canadian regions and online medical channels (Key Developments) Expanded the Spectrum Therapeutics portfolio in Australia with new CBD, THC, and balanced softgel capsules, deepening the company’s presence in the maturing Australian medical cannabis market (Key Developments) Shareholders approved amendments to the company’s articles to allow a potential consolidation of common and exchangeable shares, giving the board discretionary authority to implement a reverse split within 12 months (Key Developments) Transitioned the DOJA facility in Kelowna, British Columbia, into an exclusive medical cultivation site under a micro cultivation license, focused on small batch craft cannabis for Spectrum Therapeutics patients, including veterans (Key Developments) Appointed Tom Stewart as permanent Chief Financial Officer, formalizing his role after serving as interim CFO and leading efforts to stabilize the balance sheet, cut expenses, and improve liquidity (Key Developments) Valuation Changes Fair Value: Unchanged at approximately CA$3.30 per share, indicating no material revision to intrinsic value estimates.Narrative-Update • Nov 24
WEED: Improving Profit Margins And Share Consolidation Will Drive Future Upside
Analysts have raised their price target for Canopy Growth from $1.30 to $3.30. They cite improvements in profit margin projections and expectations of sustained profitability, despite moderated revenue growth forecasts.Analyseartikel • Nov 15
Canopy Growth Corporation's (TSE:WEED) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Canopy Growth Corporation ( TSE:WEED ) shares have had a horrible month, losing 26% after a relatively good period...Analyseartikel • Nov 10
Canopy Growth Corporation (TSE:WEED) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Last week, you might have seen that Canopy Growth Corporation ( TSE:WEED ) released its second-quarter result to the...Narrative-Update • Nov 10
WEED: Rising Discount Rate Will Pressure Share Price In The Months Ahead
Analysts have adjusted their price target for Canopy Growth downward from $2.64 to $1.30. They cited an increased discount rate as well as ongoing evaluations of profit margin and future earnings potential.Analyseartikel • Aug 30
Revenues Tell The Story For Canopy Growth Corporation (TSE:WEED) As Its Stock Soars 70%
Canopy Growth Corporation ( TSE:WEED ) shares have had a really impressive month, gaining 70% after a shaky period...Narrative-Update • Aug 07
European Expansion And Operational Improvements Will Unlock Cannabis Potential
Consensus analyst price targets for Canopy Growth have been revised lower primarily due to a marked slowdown in forecast revenue growth, resulting in a fair value decrease from CA$3.31 to CA$2.98. What's in the News Canopy Growth introduced its Canadian-grown 7ACRES brand in Australia, expanding its medical cannabis portfolio with high-THC sativa strains Ultra Jack and Jack Frost.Analyseartikel • May 18
Investors Appear Satisfied With Canopy Growth Corporation's (TSE:WEED) Prospects As Shares Rocket 40%
Those holding Canopy Growth Corporation ( TSE:WEED ) shares would be relieved that the share price has rebounded 40% in...Analyseartikel • Apr 02
What You Can Learn From Canopy Growth Corporation's (TSE:WEED) P/S After Its 28% Share Price Crash
Unfortunately for some shareholders, the Canopy Growth Corporation ( TSE:WEED ) share price has dived 28% in the last...
Neues Narrative • Mar 31
New Medical Cannabis And Vaporizer Offerings Will Expand Global Markets
Growth in the medical cannabis sector and product innovation in adult-use and premium vaporizers position Canopy for revenue and market share expansion.Analyseartikel • Feb 12
Canopy Growth Corporation's (TSE:WEED) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Unfortunately for some shareholders, the Canopy Growth Corporation ( TSE:WEED ) share price has dived 26% in the last...Analyseartikel • Dec 22
Canopy Growth Corporation's (TSE:WEED) Popularity With Investors Under Threat As Stock Sinks 26%
Unfortunately for some shareholders, the Canopy Growth Corporation ( TSE:WEED ) share price has dived 26% in the last...Analyseartikel • Nov 05
Canopy Growth Corporation (TSE:WEED) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Canopy Growth Corporation ( TSE:WEED ) shareholders are no doubt pleased to see that the share price has bounced 28% in...Analyseartikel • Aug 28
More Unpleasant Surprises Could Be In Store For Canopy Growth Corporation's (TSE:WEED) Shares After Tumbling 26%
To the annoyance of some shareholders, Canopy Growth Corporation ( TSE:WEED ) shares are down a considerable 26% in the...Analyseartikel • Aug 17
We Think Canopy Growth (TSE:WEED) Has A Fair Chunk Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Aktionärsrenditen
| WEED | CA Pharmaceuticals | CA Markt | |
|---|---|---|---|
| 7D | 1.6% | -0.9% | -0.3% |
| 1Y | -11.6% | 21.2% | 30.2% |
Rendite im Vergleich zur Industrie: WEED unter dem Niveau der Branche Canadian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 21.2% erzielte.
Rendite vs. Markt: WEED hinter dem Markt Canadian zurück, der im vergangenen Jahr eine Rendite von 30.2 erzielte.
Preisvolatilität
| WEED volatility | |
|---|---|
| WEED Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 8.5% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in CA Market | 16.3% |
| 10% least volatile stocks in CA Market | 3.7% |
Stabiler Aktienkurs: WEED hatte in den letzten 3 Monaten im Vergleich zum Canadian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: WEEDDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 14% auf 6% zurückgegangen.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| n/a | 1,128 | Luc Mongeau | www.canopygrowth.com |
Canopy Growth Corporation, zusammen mit seinen Tochtergesellschaften, engagiert sich in der Produktion, Vertrieb und Verkauf von Cannabis und Hanf-basierte Produkte für Freizeit-und medizinischen Zwecken vor allem in den Vereinigten Staaten, Kanada, Deutschland, und international. Es ist in den Segmenten Canada Cannabis, International Markets Cannabis und Storz & Bickel tätig. Das Unternehmen bietet getrocknete Blüten, vorgerollte Joints, Öle, Softgel-Kapseln, Aufgussgetränke, Esswaren mit Gummibärchen und topische Formate sowie Verdampfergeräte an.
Canopy Growth Corporation's Grundlagenzusammenfassung
| WEED grundlegende Statistiken | |
|---|---|
| Marktanteil | CA$540.36m |
| Gewinn(TTM) | -CA$262.91m |
| Umsatz(TTM) | CA$284.60m |
1.9x
Kurs-Umsatz-Verhältnis-2.1x
Kurs-Gewinn-Verhältnis Ist WEED zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| WEED Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | CA$284.60m |
| Kosten der Einnahmen | CA$205.06m |
| Bruttogewinn | CA$79.55m |
| Sonstige Ausgaben | CA$342.46m |
| Gewinn | -CA$262.91m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Aug 07, 2026
| Gewinn per Aktie (EPS) | -0.62 |
| Bruttomarge | 27.95% |
| Nettogewinnspanne | -92.38% |
| Schulden/Eigenkapital-Verhältnis | 33.5% |
Wie hat sich WEED auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/31 01:24 |
| Aktienkurs zum Tagesende | 2026/07/31 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Canopy Growth Corporation wird von 20 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |